There is a peculiar moment at the end of a scientific paper when the authors have finished explaining the disease, the trial and the result, and begin thanking the people who helped. The prose shrinks. The names arrive in a line. If you are reading quickly, you skip it. Yet this is where Kay Square Scientific often appears - not as the owner of the science, but as one of the groups that helped the science become readable.
That distinction is the company’s entire business. A clinical trial may produce a database dense enough to occupy statisticians for months. It does not produce a manuscript, a congress poster, an advisory board or a plain-language explanation by itself. Those require choices: what matters, what belongs in the foreground, what must be qualified, which claim the evidence can support and which attractive sentence it cannot.
Kay Square Scientific is a small, privately held medical-communications agency founded by Kevin D. Pawley in 2017. It works with global biopharma companies and scientific experts from the preclinical stage through launch and post-marketing use. Its public menu runs from original-research manuscripts and meta-analyses to videos, podcasts, patient resources, speaker training and virtual meetings. This sounds broad until you notice the common ingredient: evidence must travel without losing its meaning.
A company built for the handoff
Pawley came to this work by way of words. He studied English at Rutgers, worked in medical publishing and pharmaceutical promotion, and moved into medical communications in 1995. He cofounded a med-comms agency in 2003, then a small publishing house, Kay Square Press, in 2008. After selling the earlier agency and leaving it in 2016, he started Kay Square Scientific as a division of the press. The agency became an independent corporation in 2020.
The revealing part of that history is not entrepreneurial drama. It is repetition. Pawley had already seen the same problem from several seats: the scientist who understands the data may not have time to shape the paper; the client who knows the strategy may not know the journal; the editor who can polish a sentence may not understand the endpoint. Medical communications lives in those gaps.
“Quality first. Quality lasts.”Kay Square Scientific’s operating line
A boutique agency cannot win by deploying more people than a global network. Kay Square’s answer is to reduce the cost of translation inside the team. Its website says employees average 13 years in medical communications and that many colleagues have worked together for 10, 15 or 20 years. All of its scientific writers hold PharmD or PhD degrees. The team is divided into scientific writing, editorial project management and editorial support - a useful clue that the company treats coordination as a discipline, not an administrative afterthought.
What the client actually buys
The invoice is not for “good writing” in the literary sense. It is for a controlled process. Kay Square develops publication strategies, drafts manuscripts under author direction, coordinates reviews, prepares congress submissions, checks figures and references, and helps expert groups turn discussion into a record. The business model is professional services - project work and ongoing support rather than a self-serve product. Prices and revenue are private, which is normal for this corner of consulting.
Publications
Manuscripts, reviews, meta-analyses, abstracts, posters, presentations and plain-language summaries.
Medical affairs
Scientific platforms plus strategic and tactical publication plans across a product’s life.
Expert rooms
Advisory boards, roundtables, speaker materials, training and post-meeting reports.
Many formats
Patient resources, medication guides, podcasts, videos, animations, monographs and lexicons.
The customers are pharmaceutical, biotech, gene-therapy, diagnostics and device teams, alongside the researchers and clinicians who author or review the work. Public acknowledgements provide a partial view: Kay Square staff have supported publications funded by Novartis, Apellis, Sobi, FibroGen, Vaderis Therapeutics, Amgen and AstraZeneca. These acknowledgements matter because ethical medical writing should be visible. The agency is meant to help authors express the evidence, not impersonate them.
The proof sits in small type
In late 2025, the small type became unusually impressive. A phase 3 pegcetacoplan paper in the New England Journal of Medicine thanked three Kay Square writers for preparing the first draft. Another NEJM trial report credited Kay Square editorial support. In December, two phase 3 spinal muscular atrophy studies appeared in Nature Medicine with Kay Square writers acknowledged for editorial and medical-writing support.
Those credits do not mean the agency conducted the trials or owns their conclusions. They mean its writers operated in the narrow, accountable space between raw expertise and public record. That is a stronger demonstration than a case-study slogan because the contribution is disclosed in the place where scientific readers know to look.
The agency’s product is not the paper. It is the preservation of meaning while the format, audience and deadline keep changing.
The copyable part is the team design
There is a lesson here for any small professional-services firm. Kay Square has organized around handoffs. A scientist writes. A project manager holds the timetable and the review choreography. Editorial support handles the details that become disasters when everyone assumes somebody else checked them. Senior people who have worked together for years spend less time translating one another.
The second lesson is to turn values into operating constraints. Kay Square’s employees wrote the company mission and values themselves: excellence, integrity, respect and vision. The useful test is not whether those words sound noble. It is whether they change who can do the work, how review happens and what gets rejected. Doctoral qualifications for scientific writers and explicit separation of writing, project management and support are concrete answers.
Where the boutique model earns its keep
It works best when the assignment is specialized, the evidence is sensitive, senior attention matters and the client values continuity. It is less suited to commodity content at enormous volume, instant self-service production or jobs where price matters more than expert review.
That boundary is important. Experience is expensive. A compact team has finite capacity. Long working relationships can speed the familiar work while requiring deliberate effort when a new therapeutic area or a new kind of audience arrives. And no medical-communications agency can rescue a weak study design or turn an equivocal result into a sound claim. The best it can do is refuse the temptation.
This may be why Kay Square’s story feels less like the usual agency tale and more like an argument for maintenance. Medicine celebrates the discovery, the molecule and the trial. Then someone must preserve the trail of decisions, qualifications and evidence so another human being can understand it. The work is quiet because, when it succeeds, the reader notices the science instead.